{"id":"W2897636215","doi":"10.1038/s41375-018-0276-9","title":"Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma","year":2018,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":117,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; McMaster University; Juravinski Cancer Centre","funders":"Cilag; Pharmacyclics; H. Lundbeck A/S; Astellas Pharma; Genentech; AstraZeneca; Celgene; Gilead Sciences; GlaxoSmithKline; Amgen","keywords":"Ibrutinib; Bendamustine; Chronic lymphocytic leukemia; Medicine; Internal medicine; Rituximab; Placebo; Ofatumumab; Hazard ratio; Alemtuzumab; Oncology; Lymphoma; Gastroenterology; Leukemia; Confidence interval; Pathology; Transplantation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01278558,0.0008002243,0.002187021,0.0006272362,0.00026398,0.001466279,0.0008419356,0.0007268147,0.004555456],"category_scores_gemma":[0.01162096,0.0004306529,0.002332172,0.00116287,0.0002718688,0.000777072,0.000716487,0.001334395,0.0009507155],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007083002,"about_ca_system_score_gemma":0.001078602,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00156906,"about_ca_topic_score_gemma":0.004609447,"domain_scores_codex":[0.9953859,0.002520422,0.0004452059,0.0003633947,0.001036814,0.0002481971],"domain_scores_gemma":[0.9864167,0.006126009,0.004031175,0.0009533631,0.001811441,0.0006612008],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4495881,0.00186285,0.08400288,0.00981493,0.03530364,0.0005255783,0.0005978368,0.003246092,0.01658495,0.0005016756,0.05704642,0.3409251],"study_design_scores_gemma":[0.1783853,0.03563412,0.6046156,0.001381276,0.0766193,0.001482572,0.0002339641,0.001016812,0.004929028,0.001095976,0.09443835,0.0001677263],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.677937,0.2222866,0.003349853,0.00429439,0.0009604979,0.001744733,0.07324069,0.0003876252,0.01579857],"genre_scores_gemma":[0.8925486,0.02896017,0.002859896,0.004863703,0.00103078,0.001411121,0.06417454,0.000218089,0.003933122],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01278558,"threshold_uncertainty_score":0.06761736,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02888644072565415,"score_gpt":0.3082170913937413,"score_spread":0.2793306506680871,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}